• Stockholders able to exercise right to submit questions and cast votes in a timely manner
• Online stockholders’ meeting enables proposed dividend of 2.80 euros per share for 2019 to be paid on time and in full
• Baumann: “Reliability for our stockholders is very important, especially during the crisis”

Chairman of the Board of Management, Baumann: “Our emergency aid is designed to help support hospitals and hospital staff during the crisis.”

• Group sales advance by 3.5 percent (Fx & portfolio adj.) to 43.545 billion euros
• EBITDA before special items increases by 28.3 percent to 11.503 billion euros
• Core earnings per share up by 14.3 percent to 6.40 euros
• Net income rises 141.4 percent to 4.091 billion euros – gain of 1.637 billion euros on sale of Currenta stake
• Free cash flow of 4.214 billion euros above expectations
• Proposed dividend of 2.80 euros per share
• Crop Science shows solid performance in challenging environment, substantial increase in earnings due to acquired business
• Pharmaceuticals shows encouraging business development
• Sales growth at Consumer Health, earnings at prior-year level despite divestments
• Ongoing portfolio, structural and efficiency measures implemented successfully
• Glyphosate’s positive safety profile confirmed – appeal and mediation proceedings moving forward
• Outlook for 2020: increase in sales, earnings and free cash flow
• Ambitious sustainability targets set

• Werner Wenning to retire after over 50 years with Bayer
• Horst Baier proposed for election as new shareholder representative

• New herbicide molecule in early development announced; first new post-emergence mode of action for broad acre weed control in 30 years
• Bayer unveils a third pathway to breakthrough short stature corn through gene editing; two prior concepts advance to Phase 3
• Three generations of herbicide-tolerance traits in soybeans advance phases, representing the industry’s most robust pipeline of weed control biotechnology for soy
• Largest agricultural industry R&D investment of more than 2.3 billion euros annually

• “Decision of EPA corresponds to the long-standing assessments of leading international health authorities”, says Liam Condon, Bayer Board Member
• The Amicus brief of the U.S. Department of Justice in the Hardeman case also support Glyphosate´s safety

CEO Werner Baumann: “We want to help people in the affected regions quickly and effectively”

• Chairman of the Board of Management, Baumann: “As a leading innovation company, we will drive forward a reduction in greenhouse gases throughout our entire value chain”
• Numerous investors factor CDP ratings into investment decisions
• Bayer listed as a leading company by CDP every year since2005

Diegem, 18 december 2019 – De week voor Kerstmis is traditioneel de warmste, ook bij Bayer. Net zoals vorig jaar hebben de verschillende teams van de Belgische Bayer-vestigingen acties georganiseerd voor De Warmste Week. De medewerkers hebben in totaal 19.000 euro opgehaald ten voordele van de Belgische Cardiologische Liga. Het Clinical Operations team heeft de meest succesvolle actie opgezet en zal de cheque overhandigen in Kortrijk.